Biogen Inc Stock Today
| BIIB Stock | USD 172.03 1.01 0.58% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Biogen is trading at 172.03 as of the 12th of November 2024, a 0.58 percent decrease since the beginning of the trading day. The stock's open price was 173.04. Biogen has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Biogen Inc's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of September 1991 | Category Healthcare | Classification Health Care |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 145.72 M outstanding shares of which 3.07 M shares are currently shorted by private and institutional investors with about 2.26 trading days to cover. More on Biogen Inc
Moving together with Biogen Stock
Moving against Biogen Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biogen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Christopher Viehbacher | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Hedge Favorites (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Biogen Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, Nasdaq 100, NASDAQ Composite, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ 100 Pre, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Hedge Favorites, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBiogen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biogen's financial leverage. It provides some insight into what part of Biogen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biogen Inc (BIIB) is traded on NASDAQ Exchange in USA. It is located in 225 Binney Street, Cambridge, MA, United States, 02142 and employs 7,570 people. Biogen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 25.07 B. Biogen Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 145.72 M outstanding shares of which 3.07 M shares are currently shorted by private and institutional investors with about 2.26 trading days to cover.
Biogen Inc currently holds about 4.91 B in cash with 1.55 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 34.1.
Check Biogen Probability Of Bankruptcy
Ownership AllocationBiogen holds a total of 145.72 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. On October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Biogen Inc's common stock.
Check Biogen Ownership Details
Biogen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Beutel, Goodman & Company Ltd. | 2024-06-30 | 1.7 M | |
| Legal & General Group Plc | 2024-06-30 | 1.5 M | |
| Clearbridge Advisors, Llc | 2024-06-30 | 1.5 M | |
| Ameriprise Financial Inc | 2024-06-30 | 1.5 M | |
| Northern Trust Corp | 2024-06-30 | 1.4 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | |
| Amvescap Plc. | 2024-06-30 | 1.3 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 1.2 M | |
| Ubs Asset Mgmt Americas Inc | 2024-06-30 | 1.1 M | |
| Vanguard Group Inc | 2024-06-30 | 16.6 M | |
| Primecap Management Company | 2024-09-30 | 16.3 M |
Biogen Historical Income Statement
Biogen Stock Against Markets
Biogen Corporate Executives
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael CPA | Executive CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.06 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.